Doximity Launches DocDefender, Expanding Services to Safeguard Physician Privacy

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced DocDefender, a free service for physicians that tracks down and eliminates their personal contact information from public websites. In an environment of escalating violence and harassment against…

Read MoreDoximity Launches DocDefender, Expanding Services to Safeguard Physician Privacy

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients…

Read MoreFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its key secondary endpoint of overall survival (OS), for the adjuvant treatment of…

Read MoreKEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

 Pfizer Inc. (NYSE: PFE) will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 9-12. These data…

Read MorePfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions…

Read MoreCastle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Henry Schein to Webcast Third Quarter 2023 Conference Call and Provide an Update on Its Full-Year 2023 Guidance on Monday, November 13, 2023 at 10:00 a.m. ET

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2023 financial results before the stock market opens on Monday, November 13,…

Read MoreHenry Schein to Webcast Third Quarter 2023 Conference Call and Provide an Update on Its Full-Year 2023 Guidance on Monday, November 13, 2023 at 10:00 a.m. ET

Modivcare Reports Third Quarter 2023 Financial Results; Maintains Guidance

Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today reported financial results for the three and nine months ended September 30,…

Read MoreModivcare Reports Third Quarter 2023 Financial Results; Maintains Guidance